Abstract
Salivary gland carcinoma was originally classified as acinic cell carcinoma because of its histological similarity to secretory breast carcinoma. However, in 2010, Skalove et al. characterized this tumor as mammary-analogue secretory carcinoma, because like secretory breast carcinoma, it often expresses the ETV6-NTRK3 fusion oncogene. We encountered a case of mammary-analogue secretory carcinoma arising from the parotid gland. This specific diagnosis was made because (1) a follicular variant was present, (2) physaliphorous cells were observed, (3) no zymogen granules were observed, (4) the mucoid discharge in the follicular lumen was D-PAS-positive, and (5) the tumor showed immunostaining characteristics consistent with those of mammary-analogue secretory carcinoma (e.g., positive for S-100 and adipophilin). No additional treatment was administered to the patient after the resection, as the tumor is known to show a low malignancy potential and the surgical margins were negative. Tumor recurrence or metastasis has not been observed until date.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
